Art. -Nr.: HY-15999A

Cerdulatinib hydrochloride

(Synonyms: PRT062070 hydrochloride; PRT2070 hydrochloride)

8 Cited Publications

Kundenbewertung

Based on 8 publication(s) in Google Scholar

Cerdulatinib hydrochloride (PRT062070) is a selective, oral active and reversible ATP-competitive inhibitor of dual SYK and JAK, with IC₅₀s of 32 nM, 0.5 nM, 12 nM, 6 nM and 8 nM for SYK and Tyk2, JAK1, 2, 3, respectively. Cerdulatinib hydrochloride could be used to research autoimmune disease and B-cell malignancies.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.96%
CAS. Nr.: 1369761-01-2
Formel: C₂₀H₂₈ClN₇O₃S
Molecular Weight:482.00

Speicherung:

4°C, sealed storage, away from moisture.

In solvent -80°C, 2 years , -20°C, 1 year

Cerdulatinib hydrochloride Chemical Structure

CAS. Nr.: 1369761-01-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (8)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

Tyk2

0.5 nM (IC₅₀)

JAK1

12 nM (IC₅₀)

JAK2

6 nM (IC₅₀)

JAK3

8 nM (IC₅₀)

SYK

32 nM (IC₅₀)

MST1

4 nM (IC₅₀)

ARK5

4 nM (IC₅₀)

MLK1

5 nM (IC₅₀)

FMS

5 nM (IC₅₀)

AMPK

6 nM (IC₅₀)

TBK1

10 nM (IC₅₀)

MARK1

10 nM (IC₅₀)

PAR1B-a

13 nM (IC₅₀)

TSSK

14 nM (IC₅₀)

MST2

15 nM (IC₅₀)

GCK

18 nM (IC₅₀)

JNK3

18 nM (IC₅₀)

Rsk2

20 nM (IC₅₀)

Rsk4

28 nM (IC₅₀)

CHK1

42 nM (IC₅₀)

Flt4

51 nM (IC₅₀)

Flt3

90 nM (IC₅₀)

Ret

105 nM (IC₅₀)

Itk

194 nM (IC₅₀)

Alle JAK Isoform-spezifische Produkte anzeigen :

In Vitro

Cerdulatinib (0.03-4 μM) inhibits ERK Y204 phosphorylation with an IC₅₀ of 0.5 μM and reduces the ability to upregulate cellsurface expression of the early activation marker CD69 with an IC₅₀ of 0.11 μM in B cells in human whole blood^[1].
? Cerdulatinib (0.015-2 μM) inhibits FcεRI-mediated basophil degranulation with an IC₅₀ of 0.12 μM^[1].
? Cerdulatinib (0.5-4 μM) exhibits differential potency against cytokine JAK/STAT signaling pathways^[1].
? Cerdulatinib (0-15 μM; 72 hours) results in viability effects similar to that of the combines SYK plus JAK-selective inhibition^[1].
? Cerdulatinib (1-3 μM; 48 hours) induces apoptosis in BCR-signaling competent non-Hodgkin lymphoma (NHL) cell lines^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

SU-DHL4; SU-DHL6; Ramosand and Daudi cells
Concentration:

0, 1, 3 μM
Incubation Time:

48 hours
Result:

Inhibits cells viability with the IC₅₀s of 0.73-1.39 μM.

Apoptosis Analysis^[1]

Cell Line:

SU-DHL4, SU-DHL6, and Ramos cells
Concentration:

0, 1.6, 5.0, 15 μM
Incubation Time:

72 hours
Result:

Induced SU-DHL4, SU-DHL6, and Ramos cells apoptosis.

In Vivo

Cerdulatinib (0.5-5?mg/kg; twice daily p.o. for 2 weeks) elicits dose-dependent efficacy in the rat collagen-induced arthritis (CIA) model^[1].
? Cerdulatinib (twice daily p.o. for 5 days) blocks BCR-induced B-cell activation and splenomegaly in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female Lewis rats (7-8 weeks old; 159-187 g) are immunized^[1]
Dosage:

0, 0.5, 1.5, 3, 5 mg/kg
Administration:

Oral gavage twice daily for 2 weeks
Result:

Modulated inflammation in the rat CIA treatment model.
Affected anticollagen antibody formation.

Animal Model:

Balb/c mice are received BCR stimulation^[1]
Dosage:

0, 1, 5, 15, 20, 30 mg/kg
Administration:

Oral gavage twice daily for 5 days
Result:

Suppressed upregulation of splenic B-cell surface CD80/86 and CD69 by＞60%.
Inhibited mouse splenomegaly in a dose- and concentration-dependent manner.

Chemical Information

CAS. Nr. 1369761-01-2
Appearance Solid
Molecular Weight 482.00
Formel C₂₀H₂₈ClN₇O₃S
Color Off-white to light brown
SMILES

O=S(N(CC1)CCN1C2=CC=C(NC3=NC=C(C(N)=O)C(NC4CC4)=N3)C=C2)(CC)=O.Cl
Synonyms

PRT062070 hydrochloride; PRT2070 hydrochloride
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

4°C, sealed storage, away from moisture

In solvent	-80°C	2 years
	-20°C	1 year

Publications (8)

All WB

Sort by:

Journal Impact Factor

Science

The target landscape of clinical kinase drugs. [Abstract]

2017 Dec 1;358(6367):eaan4368. PMID: 29191878

Cerdulatinib hydrochloride purchased from MedChemExpress. Usage Cited in: Science. 2017 Dec 1;358(6367):eaan4368. [Abstract]

Kinobead western Blot readout for selected inhibitor:protein combinations.

Cerdulatinib hydrochloride purchased from MedChemExpress. Usage Cited in: Science. 2017 Dec 1;358(6367):eaan4368. [Abstract]

Immunoblot analysis in MV-4-11 cells and MOLM-13, FLT3-WT and FLT3-ITD transfected HEK293 cells, and Ba/F3 FLT3-ITD cells revealed FLT3 target engagement for Golvatinib and Cabozantinib.
J Ethnopharmacol

Network pharmacology integrated with experimental validation reveals the mechanism of Xanthii Fructus against allergic rhinitis via JAK2/STAT3/HIF-1α signaling pathway. [Abstract]

2025 Mar 13:343:119461. PMID: 39923957
NAR Cancer

Co-expression of CD30 and SLFN11 serves as a dual biomarker for the treatment of cutaneous T-cell lymphoma. [Abstract]

2025 Oct 7;7(4):zcaf037. PMID: 41064808
iScience

Schlafen 11 expression in human acute leukemia cells with gain-of-function mutations in the interferon-JAK signaling pathway. [Abstract]

2021 Sep 25;24(10):103173. PMID: 34693224
Int Immunol

Interleukin-35 regulates the differentiation of regulatory T cells through the JAK-STAT pathway and influences glutamine metabolism in ARDS. [Abstract]

2025 Jul 11:dxaf041. PMID: 40643216
Immunohorizons

IκB-ζ Expression Requires Both TYK2/STAT3 Activity and IL-17-Regulated mRNA Stabilization. [Abstract]

2019 May 16;3(5):172-185. PMID: 31356171
Patent

US20180263995A1.
Methods Mol Biol

Methods for High-throughput Drug Combination Screening and Synergy Scoring. [Abstract]

2018:1711:351-398. PMID: 29344898

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 20 mg/mL (41.49 mM; ultrasonic and warming and heat to 80°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0747 mL

10.3734 mL

20.7469 mL

5 mM

0.4149 mL

2.0747 mL

4.1494 mL

10 mM

0.2075 mL

1.0373 mL

2.0747 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2 mg/mL (4.15 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2 mg/mL (4.15 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2 mg/mL (4.15 mM); Clear solution

This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Coffey G, et al. The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer. J Pharmacol Exp Ther. 2014 Dec; 351(3): 538-48. [Content Brief]

[2]. Ishikawa C, et, al. Anti-adult T‑cell leukemia/lymphoma activity of cerdulatinib, a dual SYK/JAK kinase inhibitor. Int J Oncol. 2018 Oct; 53(4): 1681-1690. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0747 mL	10.3734 mL	20.7469 mL	51.8672 mL
	5 mM	0.4149 mL	2.0747 mL	4.1494 mL	10.3734 mL
	10 mM	0.2075 mL	1.0373 mL	2.0747 mL	5.1867 mL
	15 mM	0.1383 mL	0.6916 mL	1.3831 mL	3.4578 mL
	20 mM	0.1037 mL	0.5187 mL	1.0373 mL	2.5934 mL
	25 mM	0.0830 mL	0.4149 mL	0.8299 mL	2.0747 mL
	30 mM	0.0692 mL	0.3458 mL	0.6916 mL	1.7289 mL
	40 mM	0.0519 mL	0.2593 mL	0.5187 mL	1.2967 mL

Keywords

Cerdulatinib hydrochloride

8 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Cerdulatinib hydrochloride

Bioactive Compound Library Max

Bioactive Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Orally Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Obesity Compound Library

Anti-Liver Cancer Compound Library

Rare Diseases Drug Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Autoimmune Disease Compound Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

MCE Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) Cerdulatinib hydrochloride

Alle JAK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (8)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Cerdulatinib hydrochloride Related Classifications

HY-15999A Related Classifications